The company posted a 25.2% increase in net profit to Rs 1,032 crore, while EBITDA rose 20% year-on-year to Rs 1,924 crore, with EBITDA margin improving 60 basis points to 21.0%
Expects strong H2 recovery on secured orders and pipeline growth
Moderna expanded its global commercial footprint during the quarter through new partnerships, supply agreements and regulatory approvals
The life sciences and diagnostics company posted second-quarter revenue of $730 million
Pharmaceuticals sales were broadly stable at €4.46 billion, supported by continued strong demand for Bayer's newer growth products
The Wegovy franchise remains the leading branded obesity medication in the US market
PAT grows 12% to Rs. 173 crore as US formulations jump 49%; company receives 10 ANDA approvals
To support future CDMO opportunities, the company is expanding manufacturing capacity in phases, with plans to increase capacity to 1,200 KL by FY30
43 pharma units approved under RPTUAS; two common facility projects sanctioned in Solan
Regulatory clearance follows GMP surveillance inspection conducted between April 27 and May 5, 2026.
Enterprise business grows 42%, while improved product mix and higher capacity utilisation help company return to positive EBITDA despite lower revenue
API major posts strong double-digit growth in revenue and profitability, with PBT surging 61% amid robust demand for APIs and custom manufacturing
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%
The company's EBITDA grew 33.5% year-on-year to Rs. 93.1 crore, with the EBITDA margin expanding to 22.0%, an improvement of 190 basis points over the corresponding quarter last year
The company's EBITDA stood at Rs. 4,417.7 crore, up 2.7% from the corresponding quarter last year, with an EBITDA margin of 28.9%
Subscribe To Our Newsletter & Stay Updated
